PCA
GILD icon

Purkiss Capital Advisors’s Gilead Sciences GILD Stock Holding History

Purkiss Capital Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$239K Sell
1,893
-199
-10% -$26.2K 0.09% 169
2026
Q1 		$292K Buy
2,092
+50
+2% +$7K 0.13% 130
2025
Q4 		$251K Hold
2,042
– – 0.12% 145
2025
Q3 		$227K Buy
2,042
+150
+8% +$17.1K 0.11% 150
2025
Q2 		$210K Buy
+1,892
New +$201K 0.12% 141

Other funds holding GILD

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
ECSS
Eurizon Capital SGR SpA Milan $37.3B AUM

Purkiss Capital Advisors's GILD Position: Q2 2026 in Review

Purkiss Capital Advisors reduced its Gilead Sciences (GILD) stake by 9.5% in Q2 2026, selling an estimated $26.2K and leaving 1,893 shares worth $239K. The position accounts for 0.09% of the portfolio, ranked #169.

Purkiss Capital Advisors first reported a position in GILD in Q2 2025 and has held it in 5 quarters since. The position peaked at $292K in Q1 2026. 965 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Purkiss Capital Advisors held 1,893 shares of Gilead Sciences worth $239K as of Q2 2026.
  • Purkiss Capital Advisors sold 199 Gilead Sciences shares in Q2 2026, an estimated $26.2K.
  • Gilead Sciences made up 0.09% of Purkiss Capital Advisors's portfolio in Q2 2026, its #169 holding.
  • Purkiss Capital Advisors first reported a position in Gilead Sciences in Q2 2025 and has held it in 5 quarters since.
  • Purkiss Capital Advisors's Gilead Sciences position peaked at $292K in Q1 2026.
  • 965 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Purkiss Capital Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.